Home›Trial›NCT06103487
NCT06103487ENROLLING BY INVITATION

Long Term Follow-Up for RGX-111

Study Summary

RGX-111-5101 is a long-term follow up study that evaluates the long term safety of RGX-111 in participants who have received RGX-111 (a gene therapy intended to deliver a functional copy of the alpha-L-iduronidase gene (IDUA) to the central nervous system) in a separate parent study.

Conditions
Mucopolysaccharidosis I
Interventions / Drugs
No Intervention
View on ClinicalTrials.gov ↗
Sponsor
RGNX
REGENXBIO Inc
Gene Therapy
D42/100
Study Details
Enrollment7 participants
Primary Completion—
Lead SponsorREGENXBIO Inc.
Data Retrieved2026-04-11 04:25:55.708097+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 7 participants
Sponsor Catalyst Profile

REGENXBIO Inc (RGNX) is the sponsoring company for this trial. BiotechSign currently grades this company D (42/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

RGNX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.